Medical Instruments & Supplies / Healthcare MedTech
Strategic Profile
The company operates through Endoscopic Solutions Business, Therapeutic Solutions Business, and Other segments, commanding significant market share in minimally invasive medical procedures. Recent leadership transitions and strategic focus on MedTech transformation position Olympus for continued growth in high-margin medical device markets globally.
Cyborg Score Rationale
Olympus demonstrates solid fundamentals with consistent revenue growth (997B yen in 2024, up 6.5% YoY), strong analyst sentiment (5 buy recommendations vs 1 sell), and reasonable valuation at ~21x PE. However, recent CEO resignation and ongoing leadership transitions create near-term execution risks.
Top Insights
Strong market cap of approximately 2.3 trillion yen with 29,297 employees providing global reach in medical devices
Endoscopic solutions command premium positioning in minimally invasive surgical procedures across gastrointestinal, respiratory, and surgical specialties
Revenue of 997.33 billion yen in 2024 demonstrates consistent growth trajectory, with 6.53% YoY increase
Recent CEO resignation announced January 2026 indicates ongoing leadership restructuring, creating near-term operational uncertainty
Named Competitors
Stryker Surgical Instruments — Integrated surgical and orthopedic devices
Karl Storz Endoscopy — Premium surgical endoscopy solutions
Pentax Medical Endoscopes — Advanced endoscopic imaging systems
Recent Developments
(January 2026) Refreshed HR and Operations Leadership to Drive Next Phase of Global MedTech Transformation
(2024) Revenue reached 997.33 billion yen, representing 6.53% growth compared to prior year
(Historical) Pursuing microscope unit sale to private equity for estimated 300+ billion yen
Open the full interactive Olympus Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.